BFA
REGN icon

Brendel Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Brendel Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9
Closed -$5K – 236
2021
Q2 		$5K Buy
+9
New +$4.56K ﹤0.01% 232
2020
Q3 		– Sell
-3,708
Closed -$2.31M – 82
2020
Q2 		$2.31M Buy
+3,708
New +$2.1M 1.99% 19

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Brendel Financial Advisors's REGN Position: Q3 2021 in Review

Brendel Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 9 shares — an estimated $5K sold.

Brendel Financial Advisors first reported a position in REGN in Q2 2020 and held it in 2 quarters. The position peaked at $2.31M in Q2 2020. 1,018 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • Brendel Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Brendel Financial Advisors sold 9 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $5K.
  • Brendel Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Brendel Financial Advisors's Regeneron Pharmaceuticals position peaked at $2.31M in Q2 2020.
  • 1,018 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Brendel Financial Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.